

Assessment of the trial drugs ACH-0143102 and ACH-0142684, when taken by healthy men and women.

ACTRN12614000102673

Status	COMPLETED
Phase	Phase 1
Sponsor	Achillion Pharmaceuticals, Inc
Enrollment	36 participants

Key Eligibility Criteria

Inclusion (13)

- Healthy, adult, male or female subjects, 18 to 55 years of age, inclusive.
 - Continuous non smokers who have not used nicotine containing products for at least 3 months prior to the first dose.
 - Weigh at least 50kg and have a Body Mass Index (BMI) in the range 18 to 30.
 - Medically healthy with no clinically significant laboratory profiles, vital signs or ECGs; as assessed by the PI.
 - Liver function tests (serum alanine transaminase [ALT], aspartate transaminase [AST], alkaline phosphatase [ALP]) and serum bilirubin (total and direct) must be below or equal to the upper limit of normal (ULN) at screening.
- ... and 8 more (see full listing online)

Exclusion (21)

- History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease in the opinion of the PI.
 - History or presence of alcoholism and/or drug abuse within the past 2 years.
 - History or presence of hypersensitivity or idiosyncratic reaction to the study drugs or related compounds.
 - History or presence of diabetes mellitus or hyperglycemia, in the opinion of the PI.
 - Female subjects who are pregnant or lactating.
- ... and 16 more (see full listing online)

Locations (1 total)

Auckland, New Zealand